Pharmaceutical

Dive Brief: Ionis on Tuesday said its new lipid-lowering drug Tryngolza met the main goals of two Phase 3 clinical trials that could expand its use. R...

Novartis is once again taking aim at Parkinson’s disease, through a deal with Arrowhead Pharmaceuticals that could be worth billions of dollars. The d...

Today, we’re catching up after a long weekend on news involving Amgen and Replimune, as well as updates from Sanofi, Roche, Eisai and Biogen that you...

Innovators don’t just focus on what’s in front of them; they look toward the future and imagine what could be. The 21st century has brought incredible...

The biotechnology careers of John Maraganore and Clive Meanwell have brought them into collaboration time and time again. As the respective founders o...

Collaboration offers end-to-end support from donor sourcing to manufacturing Collaboration offers end-to-end support from donor sourcing to manufactur...

Deal covers biosimilars for gastroenterology, neurology and dermatology Deal covers biosimilars for gastroenterology, neurology and dermatology

When Fierce Pharma Week is upon us, we know it’s also a signal that planning season is upon us. Here are 5 trends from this season’s audio planning an...

MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma MHRA grants conditional authorisation for treatment targeting mantl...

New subcutaneous autoinjector offers at-home treatment option for patients New subcutaneous autoinjector offers at-home treatment option for patients